Publications
Download CSV
Download XLSX
Download TXT
Tables
2024 (841)
2023 (887)
2022 (831)
2021 (892)
2020 (640)
2019 (727)
2018 (651)
2017 (681)
2016 (664)
2015 (429)
2014 (376)
2013 (319)
2012 (244)
2011 (163)
2010 (139)
2000 (2)
1977 (2)
All (8488)
Infrastructure Units
Infrastructure Units list
Infrastructure Units table
Researchers
Subset
Documentation
About
Contact
Software
Login
Backlund M
JSON
CSV
XLSX
TXT
Family name
Backlund
Given name
Maria
Initials
M
ORCID
ORCID
0000-0002-6253-816X
Affiliations
SciLifeLab Drug Discovery & Development Platform, ADME of Therapeutics, Department of Pharmacy; Uppsala University; SE-751 23 Uppsala SWEDEN
3 publications
PubMed
DOI
Crossref
Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria.
Huseby DL
, Cao S,
Zamaratski E
, ...,
Hughes D
,
Karlén A
Proc. Natl. Acad. Sci. U.S.A.
121
(15) e2317274121 [2024-04-09; online 2024-04-05]
Drug Discovery and Development (DDD) [Collaborative]
PubMed
DOI
Crossref
Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors.
Brem J
,
Panduwawala T
, Hansen JU, ..., Walsh TR,
Schofield CJ
Nat Chem
14
(1) 15-24 [2022-01-00; online 2021-12-13]
Drug Discovery and Development (DDD) [Service]
PubMed
DOI
Crossref
A Series of Analogues to the AT 2R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode.
Isaksson R
,
Lindman J
,
Wannberg J
, ...,
Gising J
,
Larhed M
ChemistryOpen
8
(1) 114-125 [2019-01-00; online 2019-01-24]
Drug Discovery and Development (DDD) [Collaborative]
SciLifeLab Data Centre
Publications
9.5.1